A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

NCT03292133 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Lung Cancer

Interventions

DRUG: EGF816
DRUG: Gefitinib

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]